J&J pulls file to extend Velcade's use in EU
Pharma Times
The drugmaker was seeking approval for the use of Velcade in combination with rituximab as a treatment for patients with relapsed follicular non-Hodgkin lymphoma. However, in a statement released by the European Medicines Agency, the regulator said it ...
Janssen withdraws attempt to extend Velcade indication in EUPMLiVE
Johnson & Johnson pulls EU submission for Velcade use in NHLThe Pharma Letter
EMA: Janssen-Cilag has Withdrew Extension Application for VelcadeWall Street Journal

all 8 news articles »